Table 1 Characteristics of the included studies
Author | Year | Study period | Recruitment | Funding | Country | HPT group/IPT control group | Outcomes | Quality status | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sample size | Birth weight (g†) | Gestational age (weeks†) | Age at inclusion (days†) | Serum bilirubin at inclusion (mg/dL†) | Emitting material | Maximum irradiance (μW/cm2/nm†) | ||||||||
RCTs | ||||||||||||||
Pettersson, M | 2021 | 2016.08–2019.09 | Prospective | Yes | Sweden | 78/69 | 3598/3586 | 39/39 | 4.10/4.10 | 20.9/21.1 | LED/NA | 35/30 | ①③④ | L |
2022 | ⑤ | M | ||||||||||||
Sardari, S | 2019 | 2017.01–2017.06 | Prospective | Yes | Iran | 32/32 | NA | NA | NA | 16.0/16.6 | NA | NA | ①④⑥ | H |
Namnabati, M | ⑤ | H | ||||||||||||
Cohort | ||||||||||||||
Khajehei, M | 2022 | 2019.01–2019.12 | Retrospective | No | Australia | 243/80 | 3228/3347 | 38+6/38+4 | 3.29/3.75 | 17.0/18.1 | LED/LED | 35/35 | ①③ | M |
Coquery, S. S | 2022 | 2018.01–2020.01 | Retrospective | No | France | 39/100 | 3185/3287 | 38+6/39 | 4.58/5.00 | NA | LED/NA | 35/NA | ④ | L |
Noureldein, M | 2021 | 2018.04–2020.09 | Retrospective | No | UK | 100/50 | 3008/2897 | 37/37 | 5.00/5.00 | 15.9/16.0 | LED/NA | 35/NA | ①②④ | M |
Eggert, L. D | 1985 | 1981.08–1982.01 | Prospective | No | USA | 62/55 | NA | NA | 4.20/3.00 | 15.3/12.0 | Fluorescent/ Fluorescent | NA | ①②④⑥ | M |
Slater, L | 1984 | 1979.10–1981.08 | Prospective | Yes | USA | 25/33 | NA | 39+5/39+4 | 3.92/3.35 | 16.5/15.8 | Fluorescent/NA | NA | ①③④⑥ | L |